Real-time glioblastoma tumor microenvironment assessment by SpiderMass for improved patient management

Yanis Zirem, Léa Ledoux, Lucas Roussel, Claude Alain Maurage, Pierre Tirilly, Emilie Le Rhun, Bertrand Meresse, Gargey Yagnik, Mark J Lim, Kenneth J Rothschild, Marie Duhamel, Michel Salzet, Isabelle Fournier,

Cell Rep Med

https://doi.org/10.1016/j.xcrm.2024.101482

Abstract

Glioblastoma is a highly heterogeneous and infiltrative form of brain cancer associated with a poor outcome and limited therapeutic effectiveness. The extent of the surgery is related to survival. Reaching an accurate diagnosis and prognosis assessment by the time of the initial surgery is therefore paramount in the management of glioblastoma. To this end, we are studying the performance of SpiderMass, an ambient ionization mass spectrometry technology that can be used in vivo without invasiveness, coupled to our recently established artificial intelligence pipeline. We demonstrate that we can both stratify isocitrate dehydrogenase (IDH)-wild-type glioblastoma patients into molecular sub-groups and achieve an accurate diagnosis with over 90% accuracy after cross-validation. Interestingly, the developed method offers the same accuracy for prognosis. In addition, we are testing the potential of an immunoscoring strategy based on SpiderMass fingerprints, showing the association between prognosis and immune cell infiltration, to predict patient outcome.